Cargando…

P44 Nosocomial neurosurgical meningitis due to XDR Pseudomonas aeruginosa: clinical experience with cefiderocol

BACKGROUND: Carbapenem resistance due to MBL production is relatively uncommon in Pseudomonas aeruginosa infections in the UK. We report a case of post-operative meningitis caused by a New-Delhi MBL-producing (NDM-1) strain, outlining the microbiological and management challenges. PATIENT CASE: The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stevenson, D. R., Cherian, B. P., Kinzig, M., Sörgel, F., Wareham, D. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Posters Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849408/ http://dx.doi.org/10.1093/jacamr/dlac004.043

Ejemplares similares

Education: A compassionate use of cefiderocol to treat osteomyelitis caused by an XDR Pseudomonas aeruginosa
por: Chavda, A, et al.
Publicado: (2021)

Spontaneous Nosocomial Pseudomonas aeruginosa Meningitis Presenting as Trismus
por: Parr, C. J., et al.
Publicado: (2017)

Nosocomial meningitis associated with external ventricular drainage at neurosurgical intensive care unit
por: Kurdyumova, N, et al.
Publicado: (2015)

Successful use of prolonged cefiderocol monotherapy for the treatment of a complex pleural abscess caused by extensively drug-resistant (XDR) Pseudomonas aeruginosa
por: Brookfield, Charlotte, et al.
Publicado: (2023)

Combination of phage therapy and cefiderocol to successfully treat Pseudomonas aeruginosa cranial osteomyelitis
por: Simner, Patricia J., et al.
Publicado: (2022)

Virulence factors and integrons are associated with MDR and XDR phenotypes in nosocomial strains of Pseudomonas aeruginosa in a Venezuelan university hospital
por: Rodulfo, Hectorina, et al.
Publicado: (2019)

1111. Therapeutic Drug Monitoring of Colistin in Cerebrospinal Fluid in the Treatment of Neurosurgical Meningitis caused by Pseudomonas aeruginosa and KPC-producing Enterobacterales
por: Yasmin, Mohamad, et al.
Publicado: (2021)

XDR-Pseudomonas aeruginosa Outside the ICU: Is There Still Place for Colistin?
por: Del Giacomo, Paola, et al.
Publicado: (2022)

Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa
por: Sadek, Mustafa, et al.
Publicado: (2022)

Ceftolozane-tazobactam and Fosfomycin for rescue treatment of otogenous meningitis caused by XDR Pseudomonas aeruginosa: Case report and review of the literature
por: Frattari, Antonella, et al.
Publicado: (2018)

Age of Antibiotic Resistance in MDR/XDR Clinical Pathogen of Pseudomonas aeruginosa
por: Kothari, Ashish, et al.
Publicado: (2023)

P24 Cefiderocol activity against a multidrug-resistant (MDR) strain of Pseudomonas aeruginosa: a case report
por: Lim,, Felicia H., et al.
Publicado: (2022)

Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: Clinical observations and susceptibility testing considerations
por: Kufel, Wesley D., et al.
Publicado: (2020)

223. Clinical Characteristics and Outcomes of Acinetobacter baumannii XDR and Pseudomonas aeruginosa XDR in a Tertiary Referral Medical Center in Mexico
por: Ojeda Yuren, Alicia Sarahi, et al.
Publicado: (2023)

P196: Post-neurosurgical meningitis
por: Madan, S, et al.
Publicado: (2013)

Pseudomonas aeruginosa nosocomial meningitis following spinal anesthesia – still a significant treatment dilemma
por: Kolovani, Entela, et al.
Publicado: (2022)

Club Cell protein: a candidate diagnostic biomarker of Pseudomonas aeruginosa nosocomial pneumonia
por: Moroz, V, et al.
Publicado: (2014)

1280. In-Vitro Activity of Cefiderocol, Imipenem/Relebactam, & Ceftazidime/Avibactam in Ceftolozane/Tazobactam Resistant Strains of Multidrug Resistant Pseudomonas aeruginosa
por: Navas, Daniel, et al.
Publicado: (2020)

1246. Clinical isolates of Pseudomonas aeruginosa Harbor Preexisting Changes in TonB-dependent Receptors Associated with Decreased Susceptibility to Cefiderocol
por: Egge, Stephanie L, et al.
Publicado: (2021)

1256. Clinical Response by Minimum Inhibitory Concentrations in Carbapenem-Resistant Pseudomonas aeruginosa Infections under Cefiderocol Compassionate Use Program
por: Satlin, Michael J, et al.
Publicado: (2021)

339 An International, Multicenter, Retrospective Study of Nosocomial Pneumonia due to Pseudomonas aeruginosa
por: Micek, Scott, et al.
Publicado: (2014)

Use of Ceftolozane-Tazobactam in Patient with Severe Medium Chronic Purulent Otitis by XDR Pseudomonas aeruginosa
por: Saraca, L. M., et al.
Publicado: (2019)

Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa
por: Edgeworth, Jonathan D, et al.
Publicado: (2019)

Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance
por: Simner, Patricia J, et al.
Publicado: (2021)

1106. Evaluation of Penetration of Cefiderocol into Cerebrospinal Fluid Using a Rat Meningitis Model
por: Takemura, Miki, et al.
Publicado: (2021)

1458. Uncharted territories: applying “precision medicine” to understand the treacherous landscape of extensively and multidrug resistant (XDR and MDR) Pseudomonas aeruginosa in a patient with cystic fibrosis and lung transplantation
por: Rojas, Laura J, et al.
Publicado: (2020)

Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program
por: Satlin, Michael J., et al.
Publicado: (2023)

349. Hardware-Associated Multidrug-resistant Pseudomonas aeruginosa Meningitis Treated with Ceftolozane-Tazobactam
por: Li, Caitlin, et al.
Publicado: (2020)

Continuous vs bolus administration of imipenem in critically ill patients with ICU-acquired pneumonia
por: Sakka, S, et al.
Publicado: (2004)

Cefiderocol is an effective topical monotherapy for experimental extensively-drug resistant Pseudomonas aeruginosa keratitis
por: Romanowski, Eric G., et al.
Publicado: (2023)

Comparison of severity of illness scoring systems for patients with nosocomial bloodstream infection due to Pseudomonas aeruginosa
por: Marra, Alexandre R, et al.
Publicado: (2006)

ATP Bioluminescence Assay To Evaluate Antibiotic Combinations against Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa
por: Puig-Collderram, Berta, et al.
Publicado: (2022)

Development and Evaluation of Bacteriophage Cocktail to Eradicate Biofilms Formed by an Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa
por: Vashisth, Medhavi, et al.
Publicado: (2023)

In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019
por: Karlowsky, James A., et al.
Publicado: (2022)

648. Cefiderocol as Rescue Therapy for Pseudomonas aeruginosa and Other Difficult-To-Treat Gram-Negative Infections
por: Chou, Andrew, et al.
Publicado: (2022)

2750. Pseudomonas aeruginosa infections treated with cefiderocol: associations of site of infection and time to first dose with outcomes in PROVE (Retrospective Cefiderocol Chart Review) Study
por: Marcella, Stephen, et al.
Publicado: (2023)

Imipenem-Resistant Pseudomonas aeruginosa: Risk Factors for Nosocomial Infections
por: Onguru, Pinar, et al.
Publicado: (2008)

Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes
por: Lu, Qin, et al.
Publicado: (2014)

Post Neurosurgical Meningitis due to Colistin Heteroresistant Acinetobacter baumannii
por: Moosavian, Mojtaba, et al.
Publicado: (2014)

Risk Factors for Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections: What Is the Influence of XDR Phenotype on Outcomes?
por: Montero, María Milagro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7nmjvs8b5flb64q2qs77u8hfei